XML 24 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8
FAIR VALUE MEASUREMENTS (Tables)
6 Months Ended
Sep. 30, 2013
Fair Value Disclosures [Abstract]  
Schedule Of Financial Assets And Liabilities
The following tables present the Company’s financial assets and liabilities measured on a recurring basis using the fair value hierarchy as of September 30, 2013 and March 31, 2013 (in thousands).

Fair Value Measurements at
 
September 30, 2013
 
Level 1

Level 2

Level 3

Total
ASSETS:

 

 



Cash and cash equivalents
$
94,917

 
$
0

 
$
0


$
94,917

U.S. government and municipal obligations
39,167

 
0

 
0


39,167

Commercial paper
0

 
5,597

 
0


5,597

Corporate bonds
17,109

 
0

 
0


17,109

Certificate of deposits
0

 
2,659

 
0


2,659

Derivative financial instruments
0

 
341

 
0


341


$
151,193

 
$
8,597

 
$
0


$
159,790

LIABILITIES:

 

 



Contingent purchase consideration
$
0

 
$
0

 
$
(4,139
)

$
(4,139
)
Contingent contractual non-compliance liability
0

 
0

 
(148
)

(148
)
Derivative financial instruments
0

 
(221
)
 
0


(221
)

$
0

 
$
(221
)
 
$
(4,287
)

$
(4,508
)

Fair Value Measurements at
 
March 31, 2013
 
Level 1

Level 2

Level 3

Total
ASSETS:

 

 



Cash and cash equivalents
$
99,930

 
$
0

 
$
0


$
99,930

U.S. government and municipal obligations
31,645

 
0

 
0


31,645

Commercial paper
0

 
12,390

 
0


12,390

Corporate bonds
5,166

 
0

 
0


5,166

Certificate of deposits
0

 
4,960

 
0


4,960

Derivative financial instruments
0

 
71

 
0


71


$
136,741


$
17,421


$
0


$
154,162

LIABILITIES:

 

 



Contingent purchase consideration
$
0

 
$
0

 
$
(5,087
)

$
(5,087
)
Contingent contractual non-compliance liability
0

 
0

 
(246
)

(246
)
Derivative financial instruments
0

 
(249
)
 
0


(249
)

$
0


$
(249
)

$
(5,333
)

$
(5,582
)
Reconciliation Of Changes In Fair Value Of Level III Financial Assets
The following table sets forth a reconciliation of changes in the fair value of the Company’s Level 3 financial liabilities for the six months ended September 30, 2013 (in thousands):

Contingent
Purchase
Consideration

Contingent
Contractual
Non-compliance
Liability
Balance at beginning of period
$
(5,087
)

$
(246
)
Change in fair value (included within research and development expense)
107


98

Payments
841


0

Balance at end of period
$
(4,139
)

$
(148
)